Policy Paper

Comments on CMS Proposed Regulation to Require Drug Pricing Transparency

PhRMA December 17, 2018

PhRMA’s comments in response to the Centers for Medicare & Medicaid’s (“CMS’s”) proposed rule that would require manufacturers to state the Wholesale Acquisition Cost (“WAC” or “list price”) of a drug or biological product in direct-to-consumer (“DTC”) television advertisements.